AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally.
Good value with proven track record and pays a dividend.
Share Price & News
How has AbbVie's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4AB has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 4AB exceeded the German Biotechs industry which returned -2.9% over the past year.
Return vs Market: 4AB exceeded the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is AbbVie's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is AbbVie undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4AB (€80.6) is trading below our estimate of fair value (€153.44)
Significantly Below Fair Value: 4AB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4AB is good value based on its PE Ratio (16.1x) compared to the Biotechs industry average (36.6x).
PE vs Market: 4AB is good value based on its PE Ratio (16.1x) compared to the German market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: 4AB is poor value based on its PEG Ratio (9.8x)
Price to Book Ratio
PB vs Industry: 4AB has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4AB's forecast earnings growth (1.6% per year) is above the savings rate (-0.4%).
Earnings vs Market: 4AB's earnings (1.6% per year) are forecast to grow slower than the German market (13.1% per year).
High Growth Earnings: 4AB's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4AB's revenue (5.2% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 4AB's revenue (5.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4AB's Return on Equity is forecast to be very high in 3 years time (97.7%).
How has AbbVie performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4AB has a large one-off loss of $4.1B impacting its December 31 2019 financial results.
Growing Profit Margin: 4AB's current net profit margins (23.6%) are higher than last year (17.3%).
Past Earnings Growth Analysis
Earnings Trend: 4AB's earnings have grown by 12.6% per year over the past 5 years.
Accelerating Growth: 4AB's earnings growth over the past year (38.6%) exceeds its 5-year average (12.6% per year).
Earnings vs Industry: 4AB earnings growth over the past year (38.6%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: 4AB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is AbbVie's financial position?
Financial Position Analysis
Short Term Liabilities: 4AB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 4AB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 4AB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 4AB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: 4AB's debt is not well covered by operating cash flow (20%).
Interest Coverage: 4AB's interest payments on its debt are well covered by EBIT (12x coverage).
Inventory Level: 4AB has a low level of unsold assets or inventory.
Debt Coverage by Assets: 4AB has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
What is AbbVie's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase AbbVie before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 4AB's dividend (5.53%) is higher than the bottom 25% of dividend payers in the German market (1.52%).
High Dividend: 4AB's dividend (5.53%) is in the top 25% of dividend payers in the German market (3.92%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 4AB has been paying a dividend for less than 10 years.
Growing Dividend: 4AB's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (82.9%), 4AB's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 4AB's dividends in 3 years are forecast to be well covered by earnings (46% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Gonzalez (65yo)
Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD21.27M) is above average for companies of similar size in the German market ($USD4.64M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
|Chairman & CEO||7.1yrs||US$21.27m||0.030% $34.1m|
|Vice Chairman & President||1.2yrs||US$8.61m||0.011% $12.2m|
|Executive VP & CFO||1.3yrs||US$3.12m||0.0011% $1.2m|
|Vice Chairman of External Affairs||7.1yrs||US$11.38m||0.014% $16.0m|
|Vice Chairman & Chief Commercial Officer||0yrs||US$8.98m||0.014% $16.2m|
|Executive Vice President of Operations||0yrs||no data||0.0080% $9.2m|
|Senior VP of Research & Development and Chief Scientific Officer||0yrs||no data||0.0013% $1.5m|
|Vice President of Investor Relations||0yrs||no data||no data|
|Executive VP & Chief Human Resources Officer||0yrs||US$3.30m||0.0013% $1.5m|
|VP of Scientific Affairs & Head of AbbVie Ventures||0yrs||no data||no data|
Experienced Management: 4AB's management team is considered experienced (4.2 years average tenure).
|Chairman & CEO||7.1yrs||US$21.27m||0.030% $34.1m|
|Independent Director||7.1yrs||US$328.43k||0.0056% $6.5m|
|Independent Director||7.1yrs||US$317.86k||0.0015% $1.8m|
|Lead Independent Director||7.1yrs||US$369.33k||0.00086% $988.1k|
|Independent Director||7.1yrs||US$348.86k||0.0021% $2.4m|
|Independent Director||7.1yrs||US$328.86k||no data|
|Independent Director||7.1yrs||US$328.86k||0.00014% $160.8k|
|Independent Director||2.8yrs||US$328.86k||no data|
|Independent Director||4.1yrs||US$322.86k||no data|
|Independent Director||7.1yrs||US$350.61k||0.0018% $2.0m|
Experienced Board: 4AB's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AbbVie Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AbbVie Inc.
- Ticker: 4AB
- Exchange: DB
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$126.350b
- Listing Market Cap: US$114.890b
- Shares outstanding: 1.48b
- Website: https://www.abbvie.com
Number of Employees
- AbbVie Inc.
- 1 North Waukegan Road
- North Chicago
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABBV *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Dec 2012|
|ABBV||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Dec 2012|
|4AB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2012|
|0QCV||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Dec 2012|
|ABBV||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Dec 2012|
|4AB||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Dec 2012|
|ABBV34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1 COM USD0.01||BR||BRL||Apr 2016|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 21:38|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.